studies

1182A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
Abhasnee Sobhonslidsuk - Grant/Research Support: Merck Sharp & Dohme
corp, Eisai, Biotron; Speaking and Teaching: DKSH
The following authors have nothing to disclose: Jirachaya Wanichanuwat, Bunyong
Phakdeekitcharoen, Areepan Sophonsritsuk, Supanna Petraksa, Saowanee
Kajanachumpol, Alongkorn Pugasab, Paisan Jittorntam, Anucha Kongsomgan,
Pawin Numthavaj, Sittiruk Roytrakul
2000
Excellent outcomes of hepatitis B core antibody positive
donors with oral antiviral agent alone in liver transplantation
Tiffany C. Wong, James Fung, Kenneth S. Chok, See-Ching Chan,
Chung Mau Lo; Surgery, The University of Hong Kong, Hong
Kong, Hong Kong
Background The use of hepatitis B core antibody (HBcAb) positive
liver graft is controversial as antiviral protocol varies and
the reported risk of de novo hepatitis B infection (HBV) ranged
from 0 to 14%. Purpose To evaluate the risk of de novo HBV
infection from HBcAb positive donor to Hepatitis B surface
antigen (HBsAg) negative recipients in liver transplantation
(LT). Method This was a retrospective review of all LT from
2000 to 2014 in Queen Mary Hospital, Hong Kong. All data
were retrieved from a prospective collected database. Results
During study period, there were 1,034 LT at our center and
128(12.4%) were from HBcAb positive donors to HBsAg negative
recipients. Baseline demographics were listed in table
1. All patients received antiviral prophylaxis only; lamivudine
(n=117) and entecavir (n=11) with no hepatitis B immunoglobulin
(HBIG) at any time point. De novo HBV as defined
by HBsAg seropositive were seen in 3 (2.3%) recipients. They
were 2 pediatric and 1 adult recipients. All had detectable
HBV DNA (range from 179.3 to 373.6x10^6 copies/ml) at
time of diagnosis and 2 had YMDD mutation. Liver biopsies
were done in 2 of them and showed no evidence of fibrosis
and immunostains for HBsAg and hepatitis B core antigen
(HBcAg) werenegative. The median time from LT to de novo
HBV was 59 (9-60) months. Tenofovir were added to the 2
pediatric patients and adevofir was added to the adult patient.
All patients with de novo HBV had undetectable HBV DNA after
treatment. The median follow-up time was 71.1 (0.3 to 202.3)
months. The 1-year and 5-year overall and graft survival were
95.6%, 90.3% and 92.8% and 87.0% respectively. None had
graft failure or mortality due to HBV infection. Conclusion The
risk of de novo HBV infection is very low and had no impact on
long-term patient and graft survival. Oral antiviral agent alone
is effective and adequate to prevent de novo HBV in HBsAg
negative patients who received a HBcAB positive graft.
Table 1. Baseline demographic of our cohort
Disclosures:
The following authors have nothing to disclose: Tiffany C. Wong, James Fung,
Kenneth S. Chok, See-Ching Chan, Chung Mau Lo
2001
Early prediction of response to peginterferon for
HBeAg-positive chronic hepatitis B using HBsAg levels at
week 4 and week 8 of therapy
Milan J. Sonneveld 1 , Willem Pieter Brouwer 1 , Stefan Zeuzem 2 , Yilmaz
Cakaloglu 3 , Fehmi Tabak 4 , Krzysztof. Simon 5 , Bettina E. Hansen
1 , Harry L. Janssen 1,6 ; 1 Erasmus MC, University Medical Center
Rotterdam, Rotterdam, Netherlands; 2 Medical Clinic 1, Johan
Wolfgang Goethe University Medical Center, Frankfurt, Germany;
3 Gastroenterohepatology, Istanbul Medical University, Istanbul,
Turkey; 4 Hepatology, Cerrahpasa Medical School, Istanbul, Turkey;
5 Infectious Disease, Medical University Wroclaw, Wroclaw,
Poland; 6 Gastroenterology, University Health Network, Toronto,
ON, Canada
Background & Aims. Serum HBsAg levels can predict response
to peginterferon (PEG-IFN) at week 12 of treatment; the performance
of prediction-rules at earlier time-points is currently
unknown. Methods. HBeAg-positive patients treated with PEG-
IFN alfa-2b alone or in combination with lamivudine in a global
randomized trial were enrolled if they had available outcome
data and available HBsAg levels at week 4 and week 8 of
therapy. Relationship between HBsAg at week 4 and week 8
of treatment and response (HBeAg loss with HBV DNA